Skip to Main Content

3,883

Views

0

CrossRef citations to date

0

Altmetric

Research Paper

Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models

Brajesh P. Kaisthaa Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Gozde Kara Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Andreas Dannhornb Imaging Sciences, AstraZeneca, Cambridge, UKView further author information

,

Amanda Watkinsa Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Grace Opoku-Ansaha Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Kristina Ilievaa Oncology R & D, AstraZeneca, Cambridge, UK;c Immunooncology, MorphoSys AG, Planegg, GermanyView further author information

,

Stefanie Mullinsa Oncology R & D, AstraZeneca, Cambridge, UK;d Translational Science, F-Star, Cambridge, UKView further author information

,

Judith Andertona Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Elena Galvania Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Fabien Garcona Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Jean-Martin Lapointee Oncology Safety Pathology, AstraZeneca, Cambridge, UKView further author information

,

Lee Brownb Imaging Sciences, AstraZeneca, Cambridge, UKView further author information

,

James Haira Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Tim Slidela Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Nadia Luheshia Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Kelli Ryana Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Elizabeth Hardakera Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Simon Dovedia Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Rakesh Kumarf Oncology R & D, AstraZeneca, Gaithersburg, MD, USAView further author information

,

Robert W. Wilkinsona Oncology R & D, AstraZeneca, Cambridge, UKView further author information

,

Scott A. Hammondf Oncology R & D, AstraZeneca, Gaithersburg, MD, USAView further author information

&

Jim Eylesa Oncology R & D, AstraZeneca, Cambridge, UKCorrespondence[email protected]

https://orcid.org/0000-0001-9043-4352 View further author information